Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) Cash from Financing Activities: 2020-2024

Historic Cash from Financing Activities for Therapeutics (RAPT) over the last 5 years, with Dec 2024 value amounting to $143.1 million.

  • Therapeutics' Cash from Financing Activities rose 31147.82% to $143.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $153.3 million, marking a year-over-year increase of 10495.02%. This contributed to the annual value of $152.9 million for FY2024, which is 10463.37% up from last year.
  • According to the latest figures from Q4 2024, Therapeutics' Cash from Financing Activities is $143.1 million, which was up 20,315.83% from $701,000 recorded in Q2 2024.
  • Therapeutics' Cash from Financing Activities' 5-year high stood at $143.1 million during Q4 2024, with a 5-year trough of $106,000 in Q3 2023.
  • For the 3-year period, Therapeutics' Cash from Financing Activities averaged around $26.0 million, with its median value being $767,000 (2023).
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first plummeted by 99.39% in 2023, then spiked by 31,147.82% in 2024.
  • Quarterly analysis of 5 years shows Therapeutics' Cash from Financing Activities stood at $4.6 million in 2020, then crashed by 86.82% to $601,000 in 2021, then soared by 12,438.94% to $75.4 million in 2022, then slumped by 99.39% to $458,000 in 2023, then surged by 31,147.82% to $143.1 million in 2024.
  • Its Cash from Financing Activities stands at $143.1 million for Q4 2024, versus $701,000 for Q2 2024 and $9.0 million for Q1 2024.